|Positive WB detected in||MCF-7 cells, A549 cells, HepG2 cells|
|Positive IP detected in||HepG2 cells|
|Positive IHC detected in||human colon cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:1000-1:4000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
16036-1-AP targets Amphiregulin in WB, IP, IHC, IF, FC, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Immunogen||Amphiregulin fusion protein Ag8907|
|Calculated molecular weight||252 aa, 28 kDa|
|Observed molecular weight||43 kDa|
|GenBank accession number||BC009799|
|Gene ID (NCBI)||374|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Amphiregulin (AREG) is one of the ligands of the epidermal growth factor receptor (EGFR). AREG plays a central role in mammary gland development and branching morphogenesis in organs and is expressed both in physiological and in cancerous tissues. The AREG protein is synthesized as a 252-amino acid transmembrane precursor, pro-AREG. At the plasma membrane, pro-AREG is subjected to sequential proteolytic cleavages within its ectodomain and is then released as the soluble AREG protein. Depending on the cell type and microenvironment, AREG can be produced in multiple cellular and mature forms using alternative pro-AREG cleavage sites and glycosylation motifs. Post-translastional modfications of 50-kDa pro-AREG produces a major soluble 43-kDa form, 28-, 26-, 16-kDa membrane anchored forms, and soluble 21-, 19-, and 9-kDa forms (PMID: 9642297).
|Product Specific Protocols|
|WB protocol for Amphiregulin antibody 16036-1-AP||Download protocol|
|IHC protocol for Amphiregulin antibody 16036-1-AP||Download protocol|
|IP protocol for Amphiregulin antibody 16036-1-AP||Download protocol|
|FC protocol for Amphiregulin antibody 16036-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Loss of KIBRA function activates EGFR signaling by inducing AREG.
CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma.
IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin.
J Invest Dermatol
Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation.
Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.